Dilip Shanghvi
| Dilip Shanghvi | |
|---|---|
| Born | October 1, 1955 (age 70) Gujarat, India |
| Nationality | Indian |
| Citizenship | India |
| Religion | Jainism |
| Education | J. J. Ajmera High School University of Calcutta (BCom) |
| Alma mater | University of Calcutta |
| Occupation | Pharmaceutical executive |
| Years active | 1983–present |
| Employer | Sun Pharmaceutical Industries |
| Company | Sun Pharmaceutical |
| Organization | Sun Pharmaceutical; Reserve Bank of India central board |
| Title | Founder and managing director of Sun Pharmaceutical |
| Board member of | IIT Bombay (chairman, board of governors) Reserve Bank of India (central board) Rhodes Trust |
| Known for | Founding Sun Pharma and building India's largest pharmaceutical company |
| Awards | Padma Shri (2016) EY Entrepreneur of the Year, India (2005) |
| Net worth | About US$28.9 billion (May 2025) |
| Spouse | Vibha Shanghvi |
| Children | 2, Aalok and Vidhi |
Dilip Shanghvi (born 1 October 1955) is an Indian pharmaceutical executive who founded Sun Pharmaceutical Industries in 1983 and built it into the largest pharmaceutical company in India and one of the largest generic drug manufacturers in the world. Forbes estimated his net worth at about US$28.9 billion in May 2025, making him the fifth wealthiest person in India.
Shanghvi began with a loan from his father and a single manufacturing facility at Vapi in Gujarat, producing psychiatric medicines. The choice of therapeutic area was deliberate and characteristic: psychiatric drugs were a category the larger Indian manufacturers neglected, prescribed by a small and identifiable group of specialists whom a new company could reach with a modest sales force.
The company grew by extending the same logic into other neglected chronic-disease categories, cardiology, diabetes, ophthalmology and dermatology, and by acquisition. The most consequential purchase was Ranbaxy Laboratories in 2014, in a share transaction valued at about US$4 billion, which made Sun Pharma the largest Indian pharmaceutical company and among the leading generic manufacturers globally. Ranbaxy came with serious unresolved regulatory problems in the United States, and the integration proved considerably harder than anticipated, contributing to four years of declining profit from 2014.
The company recovered. Sun Pharma reported profits above ₹8,000 crore in 2023, and for the 2026 financial year recorded net profit of ₹11,479 crore on revenues of ₹58,220 crore, with growth concentrated in specialty medicines rather than commodity generics.
Shanghvi received the Padma Shri in 2016 and the EY Entrepreneur of the Year award for India in 2005. He was appointed to the 21-member central board of the Reserve Bank of India in January 2018, chairs the board of governors of IIT Bombay, and became a trustee of the Rhodes scholarship at Oxford in 2017. India Today ranked him eighth among India's most powerful people in 2017.
Background: Indian pharmaceuticals
The 1970 Patents Act
The Indian pharmaceutical industry exists in its present form because of a single piece of legislation.
The Patents Act of 1970 abolished product patents for pharmaceuticals in India, recognising only process patents. An Indian company could therefore manufacture any drug in the world, however recently invented, provided it devised a different process for making it.
The consequences were substantial. Indian firms developed exceptional capability in process chemistry, since inventing a cheaper route to a known molecule became the industry's core skill. Drug prices in India fell to among the lowest in the world. And a large domestic industry grew up making medicines that were under patent elsewhere.
Every significant Indian pharmaceutical company, Sun, Ranbaxy, Cipla, Dr. Reddy's and Lupin among them, was built in that environment.
TRIPS and the shift to exports
India's accession to the World Trade Organization required it to restore product patents, which it did with effect from 2005 under the TRIPS agreement.
The industry's response was to move abroad. Indian manufacturers had spent three decades learning to make complex molecules cheaply and to satisfy regulators, and they redirected that capability at the regulated generics markets of the United States and Europe, entering when patents there expired.
The American generic market rewarded a particular skill: filing an abbreviated new drug application, and where possible challenging the originator's patent to win the 180-day exclusivity that United States law grants the first successful challenger. Indian firms became the largest source of such filings.
Quality regulation
The strategy's vulnerability was regulatory. A plant supplying the United States must satisfy the Food and Drug Administration on data integrity and manufacturing practice, and the FDA increased its inspection of Indian facilities substantially from around 2008.
A series of import alerts and consent decrees followed across the industry. Ranbaxy's case was the most severe: it pleaded guilty in 2013 to felony charges relating to adulterated drugs and false statements and paid US$500 million, and several of its plants were barred from supplying the United States.
Those unresolved problems were what Sun Pharma acquired in 2014.
Early life
Shanghvi was born on 1 October 1955 into a Jain family from Gujarat and raised in Kolkata, where his father ran a small wholesale business trading generic medicines.
He attended J. J. Ajmera High School and took a Bachelor of Commerce degree from the University of Calcutta.
He worked in his father's distribution business during his early years, which gave him direct knowledge of how medicines were sold in India, which products doctors prescribed, which were profitable for a distributor and which manufacturers were reliable. That vantage point, seeing the industry from the distribution end rather than the laboratory, shaped the decision that followed: rather than continue selling other companies' products, he would manufacture his own.
Career
Founding Sun Pharma
Shanghvi founded Sun Pharmaceutical Industries in 1983 with a small loan from his father, beginning with a single facility at Vapi in Gujarat.
The company started with five psychiatric products. The choice reflected a commercial judgment rather than a scientific one. Psychiatric medicines were prescribed by psychiatrists, a small and geographically concentrated specialty, so a company with a handful of representatives could cover the entire prescribing base. The large Indian manufacturers concentrated on anti-infectives and general practice products requiring national sales forces of thousands.
The same reasoning was applied repeatedly as the company extended into cardiology, diabetes, gastroenterology, ophthalmology and dermatology: enter chronic-disease specialties where prescribing is concentrated, where patients take the medicine for years rather than days, and where the incumbents are not paying attention.
Growth and research
Profits had grown substantially by 1993, and Shanghvi began investing in dedicated research and development facilities.
The company listed and used its equity to acquire, establishing a pattern of buying underperforming manufacturers and improving them. Caraco Pharmaceutical Laboratories in Detroit gave it a United States manufacturing base from 1997; Israel's Taro Pharmaceutical Industries, acquired after a protracted and contested takeover completed in 2010, gave it a substantial dermatology business and a strong position in North America.
The Ranbaxy acquisition
In April 2014 Sun Pharma agreed to acquire Ranbaxy Laboratories from the Japanese group Daiichi Sankyo in an all-share transaction valued at about US$4 billion including debt.
Ranbaxy was the older and, historically, the more celebrated of the two companies, and had been the first Indian pharmaceutical firm to establish itself in the United States. It was also, by 2014, in serious difficulty: four of its Indian plants were barred from supplying the American market, it had pleaded guilty to federal felony charges in 2013, and Daiichi Sankyo, which had bought control in 2008, was seeking an exit.
The acquisition made Sun Pharma the largest pharmaceutical company in India and the fifth largest generic manufacturer in the world.
It also imported Ranbaxy's regulatory problems. Sun Pharma's profits declined from 2014 to 2018, its own Halol facility in Gujarat received an FDA warning letter and import alert, and remediation absorbed management attention and capital for several years. The share price fell substantially over the period.
Shanghvi's handling of that stretch is the part of his record most often examined. He remediated the plants rather than divesting them, absorbed the earnings decline without breaking up the acquired business, and redirected the company toward specialty medicines where competition is less severe than in commodity generics.
Specialty medicines
The strategic response to the difficulties of the generic business was to move into proprietary specialty products, principally in dermatology, ophthalmology and oncology, where a company can earn a margin that does not erode to nothing as competitors file.
Sun Pharma acquired Ocular Technologies in 2016, bringing the dry-eye treatment that became Cequa, and Concert Pharmaceuticals in 2023 for about US$576 million, bringing the alopecia areata treatment deuruxolitinib, marketed as Leqselvi. Its psoriasis biologic Ilumya, acquired from Almirall, became a significant product.
By the 2026 financial year the company reported net profit of ₹11,479 crore on revenues of ₹58,220 crore, with the specialty portfolio the principal driver of growth.
Business approach
Shanghvi's method has been consistent across four decades and is unusually explicit.
The first element is entering categories others neglect. Psychiatric medicines in 1983, chronic-disease specialties thereafter, and specialty branded products more recently were each chosen because the competitive intensity was lower, not because the science was more interesting.
The second is acquiring distressed assets. Caraco, Taro and Ranbaxy were all bought in difficulty, at prices reflecting that difficulty, and improved afterwards. The approach requires tolerance for problems that appear on the balance sheet immediately and are resolved slowly.
The third is a very low public profile. Shanghvi gives few interviews, avoids the conference circuit, and is among the least visible of India's largest business figures. Colleagues describe a manager who asks questions at length before deciding and who delegates operational authority once he has.
Other interests
Shanghvi's investments have extended beyond pharmaceuticals, including a substantial stake in the power and financial services group Suzlon Energy taken in 2015, and interests in oil and gas exploration.
Public roles
The Indian government appointed Shanghvi to the 21-member central board of the Reserve Bank of India in January 2018.
He is chairman of the board of governors of the Indian Institute of Technology Bombay, and was appointed a trustee of the Rhodes scholarship programme at the University of Oxford in 2017.
Honours
- Padma Shri, Government of India, 2016
- EY Entrepreneur of the Year, India, 2005
- Ranked eighth in India Today India's Most Powerful People, 2017
Personal life
Shanghvi was born into a Jain family from Gujarat and follows the Jain faith. The surname derives from a term denoting a leader of the Jain community.
He is a devotee of Shrinathji and makes regular pilgrimage with his family to Nathdwara in Rajasthan, where the deity's principal temple stands. Images of the deity are displayed at Sun Pharma's factories and offices. His visits to the Shrinathji temple have led to his occasionally being described as Vaishnav; he is Jain by birth and visits both Jain and Hindu temples.
He is married to Vibha Shanghvi. Their son Aalok and daughter Vidhi both work at Sun Pharmaceuticals, Aalok in the company's Indian business.
Despite his wealth he maintains a notably low public profile and has avoided the personal publicity common among Indian business leaders of comparable standing.
Assessment
Shanghvi built the largest pharmaceutical company in India from a single plant and a family loan, in an industry with several older and better-connected competitors, by consistently entering the parts of it that nobody was fighting over.
The Ranbaxy acquisition is the pivot of any assessment. It made Sun Pharma the largest company in its market and simultaneously imported regulatory failures that cost four years of earnings growth and a large fall in the share price. Whether it was a good transaction depends on the period examined: poor for most of a decade, and defensible by the time the acquired assets were remediated and the combined company was reporting record profits.
The move into specialty medicines is the more interesting strategic question. Indian generic manufacturers have found the transition from commodity manufacturing to proprietary products extremely difficult, because it requires clinical development, regulatory engagement and a branded sales force, none of which the generic business teaches. Sun Pharma has progressed further than its Indian peers, and whether that progress is sufficient to escape the erosion of generic economics is not yet settled.
See also
References